← SynDRA
RALTEGRAVIR
SynDRA canonical compound SYN0008539 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Mechanism of action | HIV integrase inhibitor |
|---|
| Indication | human immunodeficiency virus (HIV-1) |
|---|
| Disease area | infectious disease |
|---|
All known targets
Mechanisms of action (all sources)
- HIV integrase inhibitor
- Modulator
- pol INHIBITOR
Drug classes
- HIV Integrase Inhibitors
- Anti-HIV Agents
- Anti-Infective Agents
- Anti-Retroviral Agents
- Antiviral Agents
- Enzyme Inhibitors
- Integrase Inhibitors
- Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor
ATC classes
- J05A · DIRECT ACTING ANTIVIRALS
Cross-references
Synonyms
- MK0518
- isentress
- raltegravir potassium
- MK-0518
- L-000900612
- L000900612
- RGV
- Isentress(TM)
- K-0518
- Raltegravir (INN)
- N-(2-(4-(4-fluorobenzylcarbamoyl)
- N-((4-Fluorophenyl)methyl)-1,6-dihydro-5-hydroxy-1-methyl-2-(1-methyl-1-(((5-methyl-1,3,4-oxadiazol-2-yl)carbonyl)amino)ethyl)-6-oxo-4-pyrimidinecarboxamide
- RAL
- MK 0518
- raltegravirum
- CHEBI:82960
- DTXCID5028586
- RefChem:55964
- J05AX08
- Raltegravir (MK-0518)
- MFCD10698872
- C20H21FN6O5
- NCGC00184997-01
- RALTEGRAVIR [INN]
- CAS-518048-05-0
- Raltegravir [USAN:INN]
- UNII-22VKV8053U
- Raltegravir?
- HSDB 8124
- RLT
- RALTEGRAVIR [MI]
- Raltegravir(MK-0518)
- Raltegravir; MK-0518
- Epitope ID:231726
- RALTEGRAVIR [VANDF]
- RALTEGRAVIR [MART.]
- hydropyrimidine-4-carboxamide
- SCHEMBL51817
Reported adverse events
- Myopathy
- Rash
- Stevens-Johnson syndrome
- Fatigue
- Headache
- Insomnia
- Nausea
- Infestation
- Dizziness
- Hepatitis
- Asthenia
Look up RALTEGRAVIR in the interactive SynDRA portal →